The role of mycophenolate mofetil in clinical renal transplantation

World Journal of Urology

Volumn 14, Issue 4, 1996, Pages 249-255

  Hodge, E E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CHEMISTRY; CLINICAL TRIAL; HUMAN; KIDNEY TRANSPLANTATION; REVIEW;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0030331993     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00182076     Document Type: Article

References (26)

1. Allison AC. Eugui EM (1994) Mycophenolale mofetil (RS61443): mode of action and effects on graft rejection. In: Thomson AW, Starzl TE (eds) Immunosuppressive drugs: developments in anti-rejection therapy. Edward Arnold, London, pp 141-154
2. Allison AC. Hovi T. Watts RWE. Wehster ADB (1975) Immunological observations on patients with the Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet II: 1 179-1 183
3. Allison AC. Kowalski WJ. Muller CJ. Waters RV. Eugui EM (1993) Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25 |Suppl 2]:65-70
4. Allison AC. Eugui EM. Sollinger HW (1993) Mycophenolate mofetil (RS-61443): mechanisms of action and effects in transplantation. Transplant Rev 7: 129-139
5. Cecka JM. Terasaki PI (1994) The UNOS Scientific Registry. In: Terasaki PU. Ceeka JM (eds) Clinical transplants 1993. UCLA Tissue Typing Laboratory. Los Angeles, pp 1-18
6. Deierhoi MH. Sollinger HW. Diethelm AC. Bel/er FO, Kauffman RS ( 1993) One-year follow-up results of a phase I trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc 25:693-694
7. Ettenger RB. Mentser MI. Potter DE. Warshavv BL. Monroe S (1995) Mycophenolale mofetil in pédiatrie renal transplantation: a report of the Pédiatrie Mycophenolate Study Group (abstract 181 ). Proc Am Soc Transplant Physicians 14:118
8. Eugui EM. Mirkovich A. Allison AC (1991) Lymphocyte-selective antiproliferative and immtinosuppressive effects of mycophenolic acid in mice. Seand .1 Immunol 33: 175-183
9. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-control led study of mycophenolate motet il combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325
10. Ferguson RM, US Renal Transplant Mycophenolate Mofetil Study Group ( 1995) Efficacy of myophenolatc mofetil for the prevention of acute rejection in first cadaveric renal transplantation (abstract 1-1 ). Proc Am Soc Transplant Surg 21:31
11. Giblett ER. Anderson JE. Cohen F. Mcuwissen HJ (1972) Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet II: 1067-1069
12. Gonwa TA. US Renal Transplant Mycophenolate Mofetil Study Group (1995) Safety of mycophenolate mofetil vs. a/athioprine in primary cadaveric renal transplant (abstract 1X4). Proc Am Soc Transplant Physicians 14:119
13. Hayry P. for the International Mycophenolate Mofelil Renal Transplantation Study Group (1995) Mycophenolate mofetil for acute rejection of cadaveric renal transplants: results of a randomized, double-blind multicenter study (abstract 179). Proc Am Soc Transplant Physicians 14 :1 IS
14. Hodge E. Totoritis M. for the Renal Transplant Mycophenolate Mofetil Study Group (1995) Combination immunosuppression with mycophenolate mofetil is more effective than that with azathioprine in preventing acute rejection following primary cadaveric renal transplantation (abstract OX5). J Urol 153 [Suppl]: 400A
15. Lee WA. Gu L. Miksztal AR. Chu N. Leung K. Nelson PH (1990) Bioavailabiltiy improvement of mycophenolic acid through amino ester derivitization. Pharmacol Res 7: 161-106
16. Morris RE. Hoyt EG. Murphy MP. Eugui EM. Allison AC (1990) Mycophenolate acid morpholinoethyl ester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22:1659-1662
17. Natsumeda Y. Ohno S. Kawasaki H, Konno Y. Weber Ci. Suzuki K ( 1990) Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 265:2592-2595
18. Neylan JF. Deierhoi MH. the US Mycophenolate Mofetil Study Group I ( 1995) Dose dependent prevention of acute renal transplant rejection in African-Americans receiving mycophenolate mofetil (abstract 1X2). Proc Am Soc Transplant Physicians 14: I 19
19. Platz KP. Sechstem WO. Eckhoff DE, Suzuki Y. Sollinger HW ( 1991 ) RS-61443 reverses acute rejection in docs. Surgery 110:730-741
20. Platz KP. Eckhoff DE. Hullett DA. Sollinger HW (1991 ) Prolongation of dog renal allograft survival by RS 61443. a new. potent immunosupprcssive agent. Transplant Proc 23:497-49X
21. Roscnthal JT. for the US Renal Transplant Refractory Rejection Mycophenolate Mofetil Study Group (1995) Mycophenolate mofetil is effective treatment for refractory acute rejection in allograft recipients (abstract 1X0). Proc Am Soc Transplant Physicians 14:118
22. Sollinger HW. Beizer FO. Dcicrhoi MH. Diethelm AG. Gonwa TA. Kauffman RS. Klintmalm GB. McDiarmid SV. Roberts J. Rosenthal JT. Tomlanovich SJ ( 1992) RS-61443 (mycophenolate mofetil): a multi-center study for refractory kidney transplant rejection. Ann Surg 216:513-519
23. Sollinger HW. Deierhoi-MH. Beizer FO. Diethelm AG. Kaufman RS ( 1992) RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 53:428-432
24. Sweeney MJ. Hoffman DH. Esterman MA (1972) Metabolism and biochemistry of mycophenolic acid. Cancer Res 32: 1X03-1X09
25. US Renal Transplant Mycophenolate Mofetil Study Group ( 1995) Mycophenolate mofetil for the prevention of acute rejection in primai")' cadaveric renal allocraft recipients. Transplantation 60:225-232
26. Young CJ. Sollinger HW (1994) Mycophenolate mofetil (RS61443). In: Kupiec-Weglinski JW (ed) New immunosupprcssive modalities and anti-rejection approaches in organ transplantation. RG Landes. Austin, pp 1-17